TROD Medical Receives CE Mark Approval For Encage
Leuven, Belgium, January 11, 2016 – TROD Medical NV, the medical device company developing tools for focal ablation, today announced that it has received CE Mark Approval for its Encage™ device.
“Receiving CE Mark Approval for Encage™ is a major milestone for the Company” said Andre Faure, CEO of TROD Medical, “and builds on the US FDA 510(k) clearance secured in 2008.”
TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. Encage is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone. Encage has the potential to reduce the risk of side effects commonly associated with current treatments, including erectile dysfunction (impotence), and urinary and fecal incontinence.
About TROD Medical NV
TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.
Trod Medical’s proprietary technology, Encage™, is a confined, bipolar, RF-based, helical ablation probe enabling minimally invasive focal ablation of soft tissues. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.
Clinical studies using the Encage device for treatment of prostate cancer are being performed at world renowned centers including: University College London (UCL) Hospitals, London; the J. Lee Moffitt Cancer Centre and Research Institute, Tampa, USA; the New York University (NYU) School of Medicine, NY, USA; and the Long Island Jewish (LIJ) School of Medicine, NY, USA.
TROD Medical is a VC-backed company with two co-leads, Capricorn Venture Partners and Vesalius Biocapital. The Company is headquartered in Leuven (Belgium) and has facilities in the Tampa Bay area, Florida (USA), and Paris (France).
“Receiving CE Mark Approval for Encage™ is a major milestone for the Company” said Andre Faure, CEO of TROD Medical, “and builds on the US FDA 510(k) clearance secured in 2008.”
TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. Encage is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone. Encage has the potential to reduce the risk of side effects commonly associated with current treatments, including erectile dysfunction (impotence), and urinary and fecal incontinence.
About TROD Medical NV
TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.
Trod Medical’s proprietary technology, Encage™, is a confined, bipolar, RF-based, helical ablation probe enabling minimally invasive focal ablation of soft tissues. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.
Clinical studies using the Encage device for treatment of prostate cancer are being performed at world renowned centers including: University College London (UCL) Hospitals, London; the J. Lee Moffitt Cancer Centre and Research Institute, Tampa, USA; the New York University (NYU) School of Medicine, NY, USA; and the Long Island Jewish (LIJ) School of Medicine, NY, USA.
TROD Medical is a VC-backed company with two co-leads, Capricorn Venture Partners and Vesalius Biocapital. The Company is headquartered in Leuven (Belgium) and has facilities in the Tampa Bay area, Florida (USA), and Paris (France).